Koers Reviva Pharmaceuticals Holdings, Inc. Nasdaq
Aandelen
TZAC
US76152G1004
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 42,72 mln. 39,37 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -41 mln. -37,79 mln. | Nettowinst (verlies) 2025 * | -48 mln. -44,24 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 39,9 mln. 36,77 mln. | Nettoliquiditeiten 2025 * | 31,9 mln. 29,4 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,66
x | K/w-verhouding 2025 * |
-1,17
x | Werknemers | 15 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 82,29% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 59 | 11-12-20 | |
Narayan Prabhu
DFI | Director of Finance/CFO | 53 | 14-12-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 69 | 14-12-20 | |
Les Funtleyder
BRD | Director/Board Member | 54 | 14-12-20 |
Founder | 59 | 11-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+67,53% | 63,85 mld. | |
-0,77% | 41,83 mld. | |
+45,66% | 40,65 mld. | |
-10,72% | 27,12 mld. | |
+13,30% | 26,52 mld. | |
-22,79% | 18,69 mld. | |
+4,70% | 12,73 mld. | |
+24,10% | 12,11 mld. | |
+27,41% | 12,07 mld. |